Nov 10, 2026 4:05 pm EST Atara Biotherapeutics Announces Third Quarter 2026 Financial Results and Operational Progress
Oct 14, 2026 8:05 am EDT Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-celĀ®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration